Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Stoke Therapeutics reports a Schedule 13G/A showing beneficial ownership of 4,763,673 shares (8.1% of the class). The filing states this percentage is calculated using 59,150,790 shares outstanding as of February 28, 2026. The holdings are reported by Lynx1 Capital Management LP and Weston Nichols and consist of 4,121,244 shares previously reported for the quarter ended March 31, 2026 plus an additional 642,429 shares.
Stoke Therapeutics Schedule 13G/A (Amend. No. 3) reports that Lynx1 Capital Management and Weston Nichols beneficially own 4,121,244 shares of Stoke Therapeutics common stock, representing 7.0% of the class. The filing cites 59,150,790 shares outstanding as of February 28, 2026 from the company’s Form 10-K.
The disclosure attributes the shares to the Lynx1 Fund and a managed account, shows shared voting and dispositive power over the reported shares, and states that the Lynx1 Fund has the right to receive dividends or sale proceeds. Signatures are by Weston Nichols on behalf of Lynx1 and individually.
Stoke Therapeutics, Inc. ownership update: an amended Schedule 13G/A shows Redmile Group, LLC and related entities report beneficial ownership of common stock as of March 31, 2026. The filing states Redmile Group, LLC and Jeremy C. Green each have 4,164,120 shares (representing 6.7% of the class) and Redmile Biopharma Investments III, L.P. holds 3,505,612 shares (5.6%), based on 62,240,347 shares outstanding as of March 31, 2026. The filing attributes shared voting and dispositive power to Redmile for these holdings and includes standard disclaimers of beneficial ownership except for pecuniary interest.
The Toronto-Dominion Bank and TD Securities filed an amendment to a Schedule 13G reporting beneficial ownership of 3,175,558 shares of Stoke Therapeutics common stock, equal to 5.4%, with the position stated as of 03/31/2026. The filing is a joint statement: TD Bank reports sole voting and dispositive power over 3,173,258 shares and TD Securities Inc. reports sole voting and dispositive power over 2,300 shares. The filing includes standard disclaimers and a joint filing agreement dated 05/15/2026.
RTW Investments, LP and Roderick Wong, M.D. filed an amended Schedule 13G/A reporting shared beneficial ownership of 5,940,866 shares of Stoke Therapeutics common stock, representing 9.99% of the class. The filing states this percent assumes exercise of 317,341 warrants and uses February 28, 2026 as the as of date for 59,150,790 shares outstanding. The Reporting Persons disclose shared voting and dispositive power over the reported shares and note that RTW Funds, including RTW Master Fund Ltd., have the right to receive dividends or sale proceeds.
Stoke Therapeutics, Inc. disclosure: Wellington Management-related entities report beneficial ownership of 3,095,700 shares of Common Stock, representing 5.23% of the class as of 03/31/2026. The shares are held of record for clients of Wellington investment advisers and voting/dispositive power is shared across affiliated entities.
Stoke Therapeutics reported a first quarter 2026 net loss of $50.0 million, or $0.79 per share, as revenue normalized following a prior-year licensing milestone. Revenue was $6.2 million versus $158.6 million a year earlier, mainly because 2025 included $150.8 million of Biogen license revenue.
The company ended March 31, 2026 with $411.0 million in cash, cash equivalents and marketable securities, including $80.7 million raised via at-the-market share sales, which it expects to fund operations into 2028.
Stoke highlighted new 4-year open-label extension data for zorevunersen in Dravet syndrome showing durable seizure reductions and statistically significant cognitive and behavioral improvements, continued generally good tolerability, and progress in the global Phase 3 EMPEROR study expected to finish U.S./UK/Japan enrollment in June 2026 and support a planned rolling U.S. NDA submission starting in early 2027.
Stoke Therapeutics’ quarterly results reflect a return to typical biotech spending after last year’s one-time deal revenue. For the three months ended March 31, 2026, revenue was $6.2 million, down from $158.6 million a year ago, mainly because 2025 included $150.8 million of Biogen license revenue recognized up front.
The company reported a net loss of $50.0 million versus net income of $112.9 million in the prior-year quarter, as research and development expenses rose to $39.7 million and sales, general and administrative costs increased to $20.0 million amid late-stage development and commercial readiness for zorevunersen.
Stoke ended the quarter with $411.0 million in cash, cash equivalents and marketable securities and expects this balance to fund operations into 2028, supported in part by at-the-market equity sales that raised about $168.5 million in net proceeds across 2025 and early 2026.
Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported an open-market sale of company stock. On May 1, 2026, he sold 2,243 shares of common stock at $32.79 per share. Following this transaction, he directly holds 36,621 shares of Stoke Therapeutics common stock.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Barry Ticho adopted on November 19, 2025. Such plans are designed to allow insiders to sell shares according to a preset schedule, helping separate routine portfolio management from discretionary trading decisions.
Morgan Stanley Smith Barney LLC reports Form 144 notices for sales of Common Stock by Baruch S. Ticho, executed under 10b5-1 plans. The excerpt lists four sale dates: 03/17/2026 (6,164 shares), 03/18/2026 (6,686 shares), 03/19/2026 (1,461 shares), and 04/01/2026 (1,838 shares). Total proceeds shown per trade are included in the table.